YCANTH (cantharidin)
YCANTH is indicated for the treatment of Molluscum Contagiosum.
How YCANTH Works
The mechanism of action of cantharidin in the treatment of molluscum contagiosum is unknown.
Development Insights
Details
- Status
- Prescription
- First Approved
- 2023-07-21
- Patent Cliff
- 2041
- Routes
- TOPICAL
- Dosage Forms
- SOLUTION
YCANTH Approval History
What YCANTH Treats
1 indicationsYCANTH is approved for 1 conditions since its original approval in 2023. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Molluscum Contagiosum
YCANTH Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to YCANTH
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
3 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT03306589 results posted | 207654 | Ph 1 | completed | Lipopolysaccharide (LPS) or Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Challenge Study on Healthy Subjects |
| NCT03017846 results posted | 16-10-195 | Ph 2 | completed | Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum, Phase 2 |
| NCT02665260 results posted | 12-01-004 | Ph 2 | completed | Safety and Efficacy Study of Topical Cantharidin for the Treatment of Molluscum Contagiosum |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
YCANTH FDA Label Details
Indications & Usage
FDA Label (PDF)YCANTH is indicated for the treatment of Molluscum Contagiosum.
YCANTH Patents & Exclusivity
Patents (4 active)
Exclusivity
Pro Intelligence Preview
Deep insights for YCANTH
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2041
- • 6 active patents
Trial Analysis
- • 3 total trials
- • Stage: Declining
Competitive Landscape
- • 1 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment